1,316
Views
0
CrossRef citations to date
0
Altmetric
Letters

Letter to the editor in response to: Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence

, , , &
Pages 3638-3640 | Received 21 Apr 2021, Accepted 09 May 2021, Published online: 25 Jun 2021

References

  • Martinelli D, Fortunato F, Marchetti F, Prato R. Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence. Hum Vaccin Immunother. 2021;17(5):1546–51. doi:10.1080/21645515.2020.1816109.
  • Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, Agocs M, Serhan F, de Oliveira L, Mwenda JM, Mihigo R, Ranjan Wijesinghe P. Global, regional, and national estimates of rotavirus mortality in children< 5 years of age, 2000–2013. Clinical Infect Dis. 2016;62(suppl_2):S96–S105.
  • Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33. doi:10.1056/NEJMoa052664.
  • Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. doi:10.1056/NEJMoa052434.
  • Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD. Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006–2016. Clinical Infect Dis. 2017;65(5):840–50. doi:10.1093/cid/cix369.
  • Vesikari T, Van Damme P, Giaquinto C, Dagan R, Guarino A, Szajewska H, Usonis V. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014. Pediatr Infect Dis J. 2015;34(6):635–43. doi:10.1097/INF.0000000000000683.
  • Expert opinion on rotavirus vaccination in infancy: European Centre for Disease Prevention and Control 2017. [accessed 2021 Apr 19]. https://www.ecdc.europa.eu/en/publications-data/expert-opinion-rotavirus-vaccination-infancy.
  • Bonanni P, Villani A, Scotti S, Biasci P, Russo R, Maio T, Vitali Rosati G, Moscadelli A, Conforti G, Azzari C. The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: a continuing example of impact on public health policies. Vaccine. 2021;39(8):1183–86. doi:10.1016/j.vaccine.2021.01.019.
  • Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin. 2011;7(5):563–68. doi:10.4161/hv.7.5.15406.
  • Daskalaki I, Spain CV, Long SS, Watson B. Implementation of rotavirus immunization in Philadelphia, Pennsylvania: high levels of vaccine ineligibility and off-label use. Pediatrics. 2008;122(1):e33–8. doi:10.1542/peds.2007-2464.
  • Clayton HA, Cortese MM, Payne DC, Bartlett DL, Zimmerman LA, Williams WG, Wang M, Stockman LJ, Parashar U, Baggs J. Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule–United States, February 2006-May 2007. MMWR Morb Mortal Wkly Rep. 2008;57:398–401.
  • Rogers MAM, Kim C, Hofstetter AM. Geospatial variation in rotavirus vaccination in infants, United States, 2010-2017. Emerg Infect Dis. 2019;25(10):1993–95. doi:10.3201/eid2510.190874.
  • 2011 through 2017 Childhood Rotavirus Vaccination Coverage Trend Report 2018. Centers for Disease Control and Prevention. [accessed 2021 Apr 19]. https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/data-reports/rotavirus/trend/index.html.
  • Layton JB, Butler AM, Brookhart MA, Panozzo CA. Variation in rotavirus vaccination coding in state US Medicaid data. Vaccine. 2019;37(22):2892–95. doi:10.1016/j.vaccine.2019.02.074.
  • Marlow R, Ferreira M, Cordeiro E, Trotter C, Januário L, Finn A, Rodrigues F. Case control study of rotavirus vaccine effectiveness in Portugal during 6 years of private market use. Pediatr Infect Dis J. 2015;34(5):509–12. doi:10.1097/INF.0000000000000647.
  • Dudareva-Vizule S, Koch J, An der Heiden M, Oberle D, Keller-Stanislawski B, Wichmann O. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum Vaccin Immunother. 2012;8(10):1407–15. doi:10.4161/hv.21593.
  • Payne DC, Selvarangan R, Azimi PH, Boom JA, Englund JA, Staat MA, Halasa NB, Weinberg GA, Szilagyi PG, Chappell J. Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US Children, 2012-2013. Clinical Infect Dis. 2015;61(12):1792–99. doi:10.1093/cid/civ872.
  • Rotarix: EPAR - product information [updated 24/03/2020]. [accessed 2021 Apr 19]. https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf.
  • RotaTeq: EPAR - product information [updated 14/09/2020]. [accessed 2021 Apr 19]. https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf.
  • Quee FA, De Hoog ML, Schuurman R, Bruijning-Verhagen P. Community burden and transmission of acute gastroenteritis caused by norovirus and rotavirus in the Netherlands (RotaFam): a prospective household-based cohort study. Lancet Infect Dis. 2020;20(5):598–606. doi:10.1016/S1473-3099(20)30058-X.
  • Wikswo ME, Parashar UD, Lopman B, Selvarangan R, Harrison CJ, Azimi PH, Boom JA, Sahni LC, Englund JA, Klein EJ, et al. Evidence for household transmission of rotavirus in the United States, 2011–2016. J Pediatric Infect Dis Soc. 2019;9(2):181–87. doi:10.1093/jpids/piz004.
  • Lopman B, Vicuna Y, Salazar F, Broncano N, Esona MD, Sandoval C, Gregoricus N, Bowen MD, Payne D, Vaca M, et al. Household transmission of rotavirus in a community with rotavirus vaccination in Quininde, Ecuador. PLoS One. 2013;8(7):e67763. doi:10.1371/journal.pone.0067763.